Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Revenue (2021 - 2025)

SAB Biotherapeutics' Revenue history spans 5 years, with the latest figure at -$63462.0 for Q4 2025.

  • For Q4 2025, Revenue fell 155.33% year-over-year to -$63462.0; the TTM value through Dec 2025 reached -$240664.0, down 118.2%, while the annual FY2024 figure was $1.3 million, 40.94% down from the prior year.
  • Revenue reached -$63462.0 in Q4 2025 per SABSW's latest filing, down from -$43292.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $18.2 million in Q2 2021 to a low of -$69565.0 in Q1 2025.
  • Average Revenue over 5 years is $4.6 million, with a median of $944575.0 recorded in 2024.
  • Peak YoY movement for Revenue: soared 207.7% in 2024, then crashed 155.33% in 2025.
  • A 5-year view of Revenue shows it stood at $11.1 million in 2021, then crashed by 80.46% to $2.2 million in 2022, then crashed by 85.88% to $305011.0 in 2023, then crashed by 62.4% to $114698.0 in 2024, then plummeted by 155.33% to -$63462.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Revenue are -$63462.0 (Q4 2025), -$43292.0 (Q3 2025), and -$64345.0 (Q2 2025).